WO2014140938A3 - Méthodes immunologiques - Google Patents

Méthodes immunologiques Download PDF

Info

Publication number
WO2014140938A3
WO2014140938A3 PCT/IB2014/001268 IB2014001268W WO2014140938A3 WO 2014140938 A3 WO2014140938 A3 WO 2014140938A3 IB 2014001268 W IB2014001268 W IB 2014001268W WO 2014140938 A3 WO2014140938 A3 WO 2014140938A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunological methods
methods
reagent
disclosure relates
immunological tolerance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/001268
Other languages
English (en)
Other versions
WO2014140938A2 (fr
Inventor
Giuseppe Pantaleo
Sven LETOURNEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Universitaire Vaudois CHUV
Original Assignee
Centre Hospitalier Universitaire Vaudois CHUV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Universitaire Vaudois CHUV filed Critical Centre Hospitalier Universitaire Vaudois CHUV
Publication of WO2014140938A2 publication Critical patent/WO2014140938A2/fr
Publication of WO2014140938A3 publication Critical patent/WO2014140938A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un réactif et des méthodes permettant de rompre la tolérance immunologique périphérique.
PCT/IB2014/001268 2013-03-14 2014-03-14 Méthodes immunologiques Ceased WO2014140938A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361781077P 2013-03-14 2013-03-14
US61/781,077 2013-03-14

Publications (2)

Publication Number Publication Date
WO2014140938A2 WO2014140938A2 (fr) 2014-09-18
WO2014140938A3 true WO2014140938A3 (fr) 2015-06-25

Family

ID=51355566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/001268 Ceased WO2014140938A2 (fr) 2013-03-14 2014-03-14 Méthodes immunologiques

Country Status (1)

Country Link
WO (1) WO2014140938A2 (fr)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5274087A (en) 1986-08-13 1993-12-28 Molecular Diagnostics, Inc. cDNA coding for carcinoembryonic antigen (CEA)
ATE96168T1 (de) 1986-08-13 1993-11-15 Miles Inc Karzinoembryonisches antigen kodierende cdns.
US5122599A (en) 1986-08-13 1992-06-16 Molecular Diagnostics, Inc. CDNAS coding for members of the carcinoembryonic antigen family
EP0347425B1 (fr) 1987-03-02 1995-12-27 Whitehead Institute For Biomedical Research Vaccin mycobacterien recombinant
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
CA1341245C (fr) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Virus recombinant de la vaccine derive du virus modifie ankara
EP0326423B1 (fr) 1988-01-29 1995-05-24 Eli Lilly And Company Vecteurs, composes et procédés d'expression d'un antigène adenocarcinome humain
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
CA2076753A1 (fr) 1990-02-26 1991-08-27 Anthony J. Radford Plasmide navette de escherichia coli et de mycobacteries
GB9015888D0 (en) 1990-07-19 1990-09-05 Smithkline Biolog Vectors
US6071716A (en) 1990-10-01 2000-06-06 Dana-Farber Cancer Institute DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
WO1992015672A1 (fr) 1991-03-07 1992-09-17 Virogenetics Corporation Souche de vaccin mise au point par genie genetique
CA2102623C (fr) 1991-05-06 2003-04-22 Jeffrey Schlom Virus recombinant exprimant un antigene carcino-embryonnaire et methodes d'utilisation
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
EP0587775A4 (fr) 1991-06-06 1994-11-02 Medimmune Inc Induction de reponses de lymphocytes t cytotoxiques a des antigenes etrangers exprimes dans des mycobacteries.
AU6172194A (en) 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
WO1996010419A2 (fr) 1994-10-03 1996-04-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services, Office Of Technology Transfer Composition comprenant un virus de recombinaison exprimant un antigene et un virus de recombinaison exprimant une molecule immunostimulatrice
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US5939526A (en) 1995-03-21 1999-08-17 Ludwig Institute For Cancer Research Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
ES2281935T3 (es) 1997-10-08 2007-10-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Antigeno cancerigeno humano ny eso-1/ca6 y gen que codifica para el mismo.
BR9913311A (pt) 1998-08-31 2001-10-16 Trinity College Dublin Molécula de ácido nucleico isolado, ácido nucleico isolado, vetor, proteìna, anticorpo e anti-soros formados contra uma proteìna, kit de diagnóstico, processos para reduzir a infecção de estafilococos coagulase-negativos de um dispositivo médico de retenção, para tratar uma infecção de estafilococus coagulase-negativa, para prevenir uma infecção de estafilococos coagulase-negativa em um paciente, para induzir uma resposta imunológica e para identificar compostos que inibem estafilococos coagulase-negativos
US6329201B1 (en) 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
WO2000039318A1 (fr) 1998-12-31 2000-07-06 Chiron Corporation Compositions et methodes permettant l'encapsidation de vecteurs d'alphavirus
JP5640237B2 (ja) 1999-11-30 2014-12-17 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ リミテッド 癌関連抗原をコードする単離された核酸分子、その抗原そのものおよびその使用
DE60336653D1 (de) 2002-08-07 2011-05-19 Bavarian Nordic As Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren
US7473531B1 (en) 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANGELOS D GRITZAPIS ET AL: "Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/-tolerant mice", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 61, no. 3, 18 September 2011 (2011-09-18), pages 397 - 407, XP035018860, ISSN: 1432-0851, DOI: 10.1007/S00262-011-1113-4 *
BERNARD JC MACATANGAY ET AL: "Regulatory T cells in HIV immunotherapy", HIV THERAPY, vol. 4, no. 6, 1 November 2010 (2010-11-01), pages 639 - 647, XP055145123, ISSN: 1758-4310, DOI: 10.2217/hiv.10.51 *
CAROLA G VINUESA ET AL: "Follicular B helper T cells in antibody responses and autoimmunity", THE JOURNAL OF IMMUNOLOGY, NATURE PUB. GROUP, GB, vol. 5, no. 11, 1 November 2005 (2005-11-01), pages 853 - 865, XP008145950, ISSN: 1474-1733, DOI: 10.1038/NRI1714 *
CHIE KUDO-SAITO ET AL: "The Requirement of Multimodal Therapy (Vaccine, Local Tumor Radiation, and Reduction of Suppressor Cells) to Eliminate Established Tumors", CLINICAL CANCER RESEARCH, 15 June 2005 (2005-06-15), pages 4533 - 4544, XP055144888, Retrieved from the Internet <URL:http://clincancerres.aacrjournals.org/content/11/12/4533.full.pdf> [retrieved on 20141007], DOI: 10.1158/1078-0432.CCR-04-2237 *
GOMEZ ET AL: "Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C", VACCINE, ELSEVIER LTD, GB, vol. 25, no. 11, 13 February 2007 (2007-02-13), pages 1969 - 1992, XP005886413, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2006.11.051 *
MARY T LITZINGER ET AL: "IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 110, no. 9, 1 November 2007 (2007-11-01), pages 3192 - 3201, XP002628064, ISSN: 0006-4971, [retrieved on 20070706], DOI: 10.1182/BLOOD-2007-06-094615 *
MING-SHEN DAI ET AL: "Early Treg suppression by a listeriolysin-O-expressing E. coli vaccine in heterologous prime-boost vaccination against cancer", VACCINE, vol. 30, no. 48, 1 November 2012 (2012-11-01), pages 6903 - 6911, XP055079672, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2012.09.001 *

Also Published As

Publication number Publication date
WO2014140938A2 (fr) 2014-09-18

Similar Documents

Publication Publication Date Title
EP3017308A4 (fr) Procédés, compositions et systèmes utilisables dans le cadre d&#39;analyses microfluidiques
EP3030769A4 (fr) Moteur
EP3076967A4 (fr) Nouveaux procédés
EP3033677A4 (fr) Techniques de traitement de demandes
EP3004163A4 (fr) Procédé pour la purification d&#39;anticorps
HK1218549A1 (zh) 新型抗体框架
EP2963059A4 (fr) Anticorps dirigé contre la fibrine insoluble
EP2808235B8 (fr) Véhicule à pendule inversé
EP3060578A4 (fr) Purification d&#39;anticorps
EP2960091A4 (fr) Dispositif de moteur
EP2964776A4 (fr) Essai à multiples analytes
EP3064739A4 (fr) Dispositif moteur
EP2973078A4 (fr) Ajout de gestionnaire d&#39;évènement déclenché par la conception
EP3000267A4 (fr) Procédé de partage de ressources au moyen de traitements harq individuels
EP3065774A4 (fr) Anticorps anti-ccl17
EP3065728A4 (fr) Nouvelles méthodes
EP3044682A4 (fr) Moteur d&#39;interrogation de transaction
EP3089221A4 (fr) Module photovoltaïque double verre
EP3060916A4 (fr) Dispositifs d&#39;analyse microfluidique et leurs procédés de fabrication et d&#39;utilisation
EP3077816A4 (fr) Procédés de dosage de glucane-beta
EP3016982A4 (fr) Anticorps anti-toso
EP3075979A4 (fr) Moteur
EP3090263A4 (fr) Méthode de dosage d&#39;une compétence immunologique
EP3067546A4 (fr) Moteur
EP3009630A4 (fr) Moteur

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14752374

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14752374

Country of ref document: EP

Kind code of ref document: A2